Celsion Corporation (NASDAQ:CLSN)

CAPS Rating: 1 out of 5

A biotechnology company dedicated to furthering the development and commercialization of treatment systems for cancer and other diseases using focused heat energy in combination with other therapeutic devices or heat-activated genes.


Player Avatar riciulius (< 20) Submitted: 4/14/2011 3:18:06 PM : Outperform Start Price: $9.90 CLSN Score: -132.35

Second giant killer that is in my 20-20-20 bucket (over 20% insider, under 20 PE, within 20% of 52 week low). Look at the insider trades... they have been upping the ante significantly with each phase of the trial completed. These guys are industry vets (check the resumes) and they obviously believe that they are going to knock this out of the park. This is a ridiculously low valuation for this stock given the phase of the trial and the large market for this interesting therapy.Oh, and their patent was approved recently, so there seems to be a tight plan by management with final FDA approval set to come down the pipe soon.

Featured Broker Partners